NBIX
Neurocrine Biosciences, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
150.82
close · 2026-08-13
value
31
cheaper than peers31
quality
99
stronger fundamentals99
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
34 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 4.15× | 50 |
| forward P/E | 12.62× | 50 |
| EV to EBITDA | 20.91× | 33 |
| price to sales | 6.01× | 18 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 42.2% | 92 |
| debt to equity | 13.6% | 91 |
| operating margin | 22.8% | 81 |
| return on equity | 22.5% | 80 |
4 of 4 measures available
Facts
| market cap | $15B |
| free cash flow | $590.6M |
| employees | 2,000 |
| first trade | 1996-05-23 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-07-30 |